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Cytokine-modified tumour cells have been used in clinical trials for immunotherapy of neuroblastoma, but primary tumour cells from
surgical biopsies are difficult to culture. Autologous fibroblasts, however, are straightforward to manipulate in culture and easy to
transfect using nonviral or viral vectors. Here we have compared the antitumour effect of fibroblasts and tumour cells transfected ex
vivo to coexpress interleukin-2 (IL-2) and IL-12 in a syngeneic mouse model of neuroblastoma. Coinjection of cytokine-modified
fibroblasts with Neuro-2A tumour cells abolished their in vivo tumorigenicity. Treatment of established tumours with three
intratumoral doses of transfected fibroblasts showed a significant therapeutic effect with reduced growth or complete eradication of
tumours in 90% of mice, associated with extensive leukocyte infiltration. Splenocytes recovered from vaccinated mice showed
enhanced IL-2 production following Neuro-2A coculture, and increased cytotoxicity against Neuro-2A targets compared with
controls. Furthermore, 100% of the tumour-free mice exhibited immune memory against tumour cells when rechallenged three
months later. The potency of transfected fibroblasts was equivalent to that of tumour cells in all experiments. We conclude that
syngeneic fibroblasts cotransfected with IL-2 and IL-12 mediate therapeutic effects against established disease, and are capable of
generating immunological memory. Furthermore, as they are easier to recover and manipulate than autologous tumour cells,
fibroblasts provide an attractive alternative immunotherapeutic strategy for the treatment of neuroblastoma.
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Neuroblastoma is one of the most common solid tumours of
childhood, accounting for 8–10% of all childhood cancers and 15%
of cancer-related deaths (Young and Miller, 1975). The tumours
may arise wherever neural crest cells occur, the most frequent
locations being the adrenal medulla and sympathetic ganglia. Age
of diagnosis is critical to outcome, and infants diagnosed in the first
12 months generally have a promising prognosis, even if suffering
from metastatic disease. Those diagnosed over 1 year of age have a
less favourable outlook and often fail to respond even to the most
aggressive combinations of therapy. The current treatment for
neuroblastoma patients with severe disease is usually chemother-
apy, followed by surgical resection or radiotherapy (Pinkerton et al,
2000). Treatment for minimal residual disease involves high-dose
chemotherapy with autologous stem cell rescue, or differentiation
of the remaining malignant cells with retinoids (Philip et al, 1997).
Patients with disseminated disease, however, frequently relapse,
and so alternative treatments including immunotherapy are under
investigation.
Immunotherapy using tumour cells transduced with single-
chain interleukin-12 (IL-12) protein has shown promise in murine
models of neuroblastoma (Lode et al, 1998b), an effect that was
enhanced in combination with tumour-targeted interleukin-2 (IL-2)
protein (Lode et al, 1999). In natural killer (NK) cells, IL-2 was
shown to enhance the antitumour activity of IL-12 through the
upregulation of IL-12 receptors and STAT4 (Wang et al, 2000).
Interleukin-12 also induces CD25 expression on T cells, thereby
enhancing their proliferation in response to IL-2 (Nguyen et al,
2000). We have demonstrated previously that Neuro-2A murine
neuroblastoma cells could be transfected simultaneously with two
plasmids using a synthetic vector system to express high levels of
both IL-2 and single-chain IL-12 (Siapati et al, 2003). Transfection
of Neuro-2A cells with IL-2 and IL-12 abolished their tumorigeni-
city in syngeneic A/J mice, and when injected into established
tumours provoked an antitumour immune response involving
CD8
þ and CD4
þ T cells, which led in some cases to complete
tumour eradication.
Cytokine adjuvant immunotherapy strategies for neuroblastoma
have been investigated clinically with both autologous and
allogeneic neuroblastoma tumour cells transduced with IL-2
(Bowman L et al, 1998; Bowman LC et al, 1998). Autologous cells
were much more effective in these studies, but the difficulty of
establishing cultures of purified primary neuroblastoma tumour
cells rapidly has limited the wider exploitation of this approach.
Fibroblast cultures from skin biopsies are relatively easy to
establish and expand, and so autologous fibroblasts gene-modified
to express cytokine adjuvants may offer a viable alternative to
autologous tumour cells as cellular vaccines. Autologous fibro-
blasts transduced with IL-2 and mixed with autologous irradiated
tumour cells have been used in phase I trials to treat colorectal
carcinoma (Sobol et al, 1999), and IL-12-transduced autologous
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sfibroblasts have been used to treat melanoma (Kang et al, 2001),
both with promising results. However, so far there are no reports
of autologous fibroblast therapy for neuroblastoma. In this study,
we have compared the potential of IL-2- and IL-12-transfected
murine syngeneic fibroblasts with IL-2- and IL-12-transfected
tumour cells to generate an immune response in mice with an
established tumour burden, and to establish protective immunity
from tumour rechallenge.
MATERIALS AND METHODS
Cell culture
Murine neuroblastoma cells (Neuro-2A) (ATCC, Teddington, UK)
were maintained in Dulbecco’s modified Eagle’s medium (DMEM)-
Glutamax-1 (Invitrogen, Paisley, UK) containing 10% foetal calf
serum (FCS) (Sigma, Poole, UK), 100IUml
 1 penicillin,
100mgml
 1 streptomycin, 1% sodium pyruvate and 1% non-
essential amino acids (Invitrogen, Paisley, UK). AJ3.1 is a mouse
embryonic fibroblast line derived from A/J embryos 13.5 days
postcoitum as follows: the crania and red organs were removed
and the remaining tissue minced using scalpels, digested with
trypsin, then passed through a cell strainer. The resulting
suspension was plated in DMEM containing 10% FCS and
antibiotics, with each embryo maintained as a separate culture.
Cells were passaged every few days to maintain sparse colonies
until the cultures reached senescence, and after 7–10 days growing
colonies of cells were observed. One culture was selected for all
further work and is hereafter referred to as AJ3.1.
Plasmids
Human IL-2 gene was expressed from pCI-hIL-2 (Siapati et al,
2003). Murine IL-12 was expressed from the plasmid pCI-mIL-12,
which was generated by subcloning into pCI (Promega, South-
ampton, UK) the gene encoding the single-chain fusion protein of
the p35 and p40 subunits of murine IL-12 separated by a flexible
linker, from plasmid pcDNA3.1scIL12 (Lode et al, 1998a). All
plasmids were grown in Escherichia coli DH5a and purified using
the EndoFree Mega plasmid kit (Qiagen, Crawley, UK).
Transfections
All cells were transfected using the lipid:peptide:DNA plasmid
(LPD) vector, as described previously (Hart et al, 1998). AJ3.1 cells
were transfected using a peptide identified by phage display that
binds to fibroblasts (gift from A Kritz, unpublished data). Neuro-
2A cells were transfected with peptide 6 containing the a5b1
integrin-specific RRETAWA-binding domain isolated from a
phage display library (Koivunen et al, 1994). The lipid used was
Lipofectin (Invitrogen Ltd, Paisley, UK). All transfections were
carried with a weight ratio of 0.75L:4P:1D in OptiMEM
(Invitrogen, Paisley, UK) serum-free medium for 4h before being
replaced with complete medium.
AJ3.1 fibroblasts and Neuro-2A neuroblastoma cells were
transfected with cytokine plasmids and supernatant was harvested
for 5 days. Human IL-2 (hIL-2) and murine IL-12 (mIL-12p70)
expression levels were determined by DuoSet ELISA Development
System (R&D Systems, Abingdon, UK) according to the manu-
facturer’s instructions.
For cells used in vaccinations, 3 10
6 AJ3.1 fibroblasts were
plated per 150cm
2 flask, and transfected for 4h with LPD
complexes containing 80mg DNA (40mg each of pCI-hIL-2 and
pCI-mIL-12). 4 10
6 Neuro-2A cells were plated per 150cm
2 flask
and transfected with the LPD vector containing 80mg DNA. After
24h, cells were harvested by trypsinisation and stored frozen until
required for vaccination. On the day of use, cells were thawed,
washed in RPMI medium before injection into the tumour.
Animal vaccinations
All animal procedures were approved and licensed by the Home
Office and performed to the standards required by the UK Co-
ordinating Committee on Cancer Research (UKCCCR) (Workman
et al, 1998). Female A/J mice of 5–7 weeks old were purchased
from Harlan Laboratories (Oxford, UK). For tumorigenicity
experiments, transfected or control AJ3.1 or Neuro-2A cells were
trypsinised 24h after transfection, washed and resuspended at
10
7cellsml
 1. Mice were vaccinated by injection in the left
posterior flank with 10
6 wild-type Neuro-2A cells in combination
with 10
6 AJ3.1 cells, 10
6 Neuro-2A cells transfected with IL-2 and
IL-12 (Neuro-IL2/12) or 10
6 AJ3.1 fibroblast cells transfected with
IL-2 and IL-12 (AJ-IL2/IL12) (n¼6 per group). Control animals
received 10
6 viable Neuro-2A tumour cells only. Tumour progres-
sion was monitored by measuring two perpendicular axes every
2–3 days using callipers. Mice were promptly culled if the tumour
reached a diameter of 12mm or was ulcerating. For vaccination
experiments in mice with an existing tumour burden (n¼16),
mice were engrafted with 10
6 unmodified Neuro-2A cells
subcutaneously (s.c.) in the left posterior flank. On day 3 after
injection of tumour cells, when tumours had reached approxi-
mately 2 2mm, animals were vaccinated by intratumoral (i.t.)
injection with 10
6 Neuro-IL2/IL12, 10
6 AJ-IL2/IL12 or by
peritumoral injection if it was too difficult to inject inside the
tumour. Control animals received 100ml RPMI (Invitrogen,
Paisley, UK) medium only. All groups of mice received three
doses of their vaccine, 2 days apart, on days 3, 5 and 7. Mice
remaining tumour free 3 months after the initial injection were
rechallenged with 10
6 viable Neuro-2A cells in the opposite flank to
the first injection and tumour progression was monitored. These
rechallenged mice, which remained tumour free for a further 3
months, were culled and their splenocytes used for in vitro assays.
Enzyme-linked immunosorbent spot assays (ELISpot)
Spleen cells were washed through cell strainers using RPMI to give
single-cell suspensions. Cells were pelleted by centrifugation
(240 g) and erythrocytes were removed by lysis on ice for
5min with 0.83% ammonium chloride. Remaining cells were then
resuspended at 5 10
6 cellsml
 1 in RPMI, and then aliquoted into
96-well U-bottomed plates with 5 10
3 Neuro-2A cells as targets at
an effector:target (E:T) ratio of 100:1. Positive-control wells
contained effector cells in 5mgml
 1 Concanavilin A and negative
controls contained effector cells only. Plates were incubated
overnight, then the contents of each well were transferred to 96-
well MultiScreen Immobilon-P plates (Millipore, MA, USA) coated
with 1mgml
 1 anti-mIL-2 (clone JES6-1A12; Pharmingen, San
Diego, CA, USA), which had been blocked with FCS for 30min and
washed with wash buffer (PBS). Plates were incubated at 371C and
5% CO2 for 24h, then cells were washed off with wash buffer. Then,
2mgml
 1 biotinylated anti-mIL-2 (clone JES6-5H4, Pharmingen,
San Diego, CA, USA) was added in wash buffer and incubated for
2h, washed off and replaced with streptavidin-alkaline phospha-
tase (AP) conjugate (ExtrAvadin, Sigma, Dorset, UK) for 30min.
Spots were developed using AP substrate (BioRad, Hemel
Hempstead, UK) and plates were read on a Bioreader 3000 LC
plate reader (Biosys GmbH, Frankfurt, Germany).
Lactate dehydrogenase release assay
Splenocytes prepared as above were plated into 24-well plates at
10
6 cellsml
 1 in RPMI containing 10% FCS, antibiotics and 60IU
rhIL-2 (Peprotech, London, UK) and cocultured with irradiated
Neuro-2A cells at an E:T ratio of 50:1. After 4 days, a lactate
dehydrogenase (LDH) assay was performed with CytoTox96 Non-
Radioactive Cytotoxicity Assay kit (Promega, Southampton, UK).
Cytotoxic T lymphocyte (CTL) effectors were cocultured in
Immunotherapy for neuroblastoma
SE Barker et al
211
British Journal of Cancer (2007) 97(2), 210–217 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
squadruplicate in RPMI-Glutamax-1 without phenol red (Invitro-
gen, Paisley, UK), containing 5% FCS and antibiotics in U-
bottomed 96-well plates with 5 10
3 viable Neuro-2A cells at an
E:T ratio of 27:1 in 200ml. Spontaneous effector release controls
were set up in quadruplicate. Plates were incubated for 5h at 371C,
then 50ml supernatant was transferred to a flat-bottomed, 96-well
plate and assay substrate added to each well. Plates were developed
for 30min and then read in a plate-reading Lucy 1 spectro-
photometer (Anthos, Salzburg, Austria) at 492nm and the
percentage cytotoxicity was calculated using the formula:
% cytotoxicity ¼ð ð experimentalrelease
  effectorspontaneousrelease
  targetspontaneousreleaseÞ
 ð targetmaximumrelease
  targetspontaneousreleaseÞÞ 100:
Histological analysis
Tumours were excised from the same mice that were used for the
LDH and ELISpot assay, fixed in 4% PFA, embedded in paraffin
wax and 7mm sections mounted on polylysine-coated slides. For
histological analysis, sections were serially rehydrated and stained
with haemotoxylin and eosin, followed by serial dehydration with
ethanol and mounting with glass coverslips. For immunostaining
with anti-mouse-CD45 to determine the leukocyte infiltration,
sections were serially dehydrated, then microwaved in antigen-
unmasking solution for 10min. Endogenous peroxidase activity
was blocked (0.3% H2O2 (vv
 1), 0.1% NaN3 (wv
 1) in PBS) for
15min, then slides were washed in PBS. Sections were blocked with
PBS containing 10% rabbit serum (vv
 1) (Vector Laboratories,
Peterborough, UK) at room temperature (RT) for 30min. Excess
block was removed, then a 1:20 dilution of unconjugated rat anti-
mouse CD45 (Pharmingen, San Diego, CA, USA) in PBS containing
1% BSA was applied. Sections were incubated overnight in a
humid chamber at 41C. Control slides were incubated with 10%
rabbit serum in PBS. Sections were washed in PBS, then a 1:250
dilution rabbit anti-rat biotinylated antibody (Dako, Glostrup,
Denmark) in PBS was added and incubated at RT for 30min. Slides
were washed and then incubated with a streptavidin-biotinylated
peroxidase complex for 30min (ABC Reagent, Vector Laboratories,
CA, USA). Positively stained cells were identified with 3,30-
Diaminobenzidine (Sigma FAST DAB, Sigma Chemical Co.,
Dorset, UK). Sections were counterstained in Methyl Green
(Vector Laboratories, CA, USA), washed twice in dH2O, dehy-
drated in butan-1-ol, then incubated in Histoclear for 10min and
air dried. Slides were mounted with glass coverslips and analysed
with an AxioPhot 2 microscope (Zeiss, Welwyn Garden City, UK)
attached to a ProgRes 3012 digital camera (Kontron Electronic,
Chichester, UK) and images were analysed using Adobe Photoshop
(Adobe Systems, San Jose, CA, USA).
Statistical analysis
The two-sample Student t-test was used to assess the significance
between experimental animal groups. Statistical significance was
taken as Po0.05.
RESULTS
Abolished in vivo tumorigenicity of neuroblastoma cells
when injected simultaneously with cytokine-transfected
fibroblasts
First, the cytokine secreting potential of syngeneic fibroblasts was
assessed. AJ3.1 fibroblast cells were transfected with pCI-hIL2 and
pCI-mIL12 under optimised transfection conditions, and super-
natants were harvested over 5 days, then secreted cytokines were
quantified by ELISA. Peak cytokine levels from cytokine-
transfected AJ3.1 cells (1100ng10
6cells
 124h
 1 of mIL-12 and
230ng10
6cells
 124h
 1 of hIL-2) were similar to those previously
observed in transfected Neuro-2A cells (1350ng10
6cells
 124h
 1
mIL-12 and 150ng10
6cells
 124h
 1 hIL-2) (Siapati et al, 2003).
For vaccine studies, a large population of cells was transfected,
and stored frozen so that the same cellular vaccine was used in all
experiments. A/J mice were injected s.c. in the left flank with 10
6
untransfected Neuro-2A alone, or in combination with 10
6 Neuro-
IL2/IL12 cells, 10
6 AJ-IL2/IL12 cells or 10
6 untransfected AJ3.1
cells. All mice receiving untransfected Neuro-2A cells alone or in
combination with untransfected AJ3.1 cells developed fast-growing
tumours by days 11 and 9, respectively. Only one of six mice (17%)
in each group treated with the Neuro-IL2/IL12 vaccine or the AJ-
IL2/IL12 vaccine developed a tumour (Figure 1) and the other five
in each group (83%) remained tumour free for over 40 days, a
significant improvement over controls (Po0.01). Therefore, the
antitumour efficacy of cytokine-transfected AJ3.1 fibroblast
vaccine was equivalent to the Neuro-2A tumour cell vaccine.
Effective treatment of established tumours with
the AJ-IL2/IL12 vaccine
The most clinically relevant aspect of any tumour vaccine is the
ability to mediate therapeutic responses against established
tumours. Neuro-2A cells were engrafted in the left flank of A/J
mice and when tumours were palpable (B3 days), mice were
vaccinated every 2 days for a total of three doses with Neuro-IL2/
IL12 or AJ-IL2/IL12 cells (n¼16 per group) or with RPMI medium
(n¼6), by i.t. injection. Each dose of cellular vaccine was from the
same, single-transfected source. Six mice from each group having
the biggest tumours were killed for in vitro analysis of the cellular
immune response at 12 days post engraftment, which was the point
when all the control mice had to be killed due to their tumour size.
The other 10 mice from each therapeutic group were monitored for
several months to study the long-term effect of vaccination on
established tumours or killed if the tumour size reached a diameter
of about 12mm.
In groups of mice (n¼10) monitored for several months to
study the long-term effect of vaccination on established tumours,
only three of 10 mice (30%) in the group treated with the
Neuro-IL2/IL12 vaccine and one of 10 mice (10%) in the group
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Figure 1 In vivo tumorigenicity of 10
6 unmodified Neuro-2A cells when
coinjected subcutaneously with 10
6 unmodified AJ3.1, 10
6 cytokine-
transfected AJ3.1 cells or 10
6 cytokine-transfected Neuro-2A in syngeneic
mice (n¼6 per group). In total, 83% of mice in the therapeutic groups did
not develop tumours and remained tumour free for over 40 days, while
control mice receiving unmodified AJ3.1þNeuro-2A or Neuro-2A only all
developed aggressive tumours within 11 days.
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streated with the AJ-IL2/IL12 vaccine developed tumours (Figure 2).
Seven mice (70%) of the Neuro-IL2/IL12 vaccine group and nine
(90%) of the AJ-IL2/IL12 vaccine group remained tumour free for
over 3 months, a significant improvement over the control group
where 100% of the mice developed tumours and were killed at 12
days post engraftment (Po0.01).
Intratumoral treatment with the Neuro-IL2/IL12 vaccine re-
sulted in significant tumour growth retardation compared to
control mice receiving RPMI. Average tumour growth was reduced
significantly by day 12 post engraftment to 36747mm
3 compared
to control mice receiving RPMI, where the average tumour volume
was 7677423mm
3 (Po0.001) (Figure 3). In the group of animals
where the AJ-IL2/IL12 vaccine was used to treat established
tumours, a significant reduction in tumour growth was also
observed at 12 days (81755mm
3) compared with RPMI-treated
controls (Po0.001) (Figure 3).
Cellular immune response
The cellular antitumour immune response after vaccination was
assessed by isolating splenocytes from six mice per group for in
vitro analysis at 12 days post engraftment (Figure 4A). Splenocytes
from mice receiving AJ-IL2/IL12 i.t. secreted high amounts of IL-2
(123712 spots) in response to coculture with wild-type Neuro-2A
cells. This result was similar to the number of spots produced by
splenocytes from mice receiving Neuro-IL2/IL12 (128715 spots).
Both groups of vaccinated mice produced significantly more spots
than RPMI-treated controls (Po0.01).
The cytotoxicity of CTL effectors was examined by LDH release
from target Neuro-2A cells. Cytotoxic T lymphocytes, obtained by
4-day culture of splenocytes (n¼6 per group) with irradiated
Neuro-2A targets in the presence of rhIL-2, were cocultured with
viable Neuro-2A for 5h at an E:T ratio of 27:1 (Figure 4B). LDH
released into the supernatant was assayed and used to calculate
percentage cytotoxicity. Splenocytes from mice vaccinated i.t.
with Neuro-IL2/IL12 showed significantly greater cytotoxicity
(1772.5%) compared to RPMI-treated controls (678%),
Po0.05. Similarly, mice vaccinated i.t. with AJ-IL2/IL12 also
exhibited greater cytotoxicity against Neuro-2A targets (1575%)
compared to RPMI-treated controls, Po0.05. Overall, there was no
significant difference in cytotoxicity of CTLs from mice receiving
either the Neuro-IL2/IL12 or AJ-IL2/IL12 vaccines.
These findings indicated that the antitumour efficacy of
cytokine-transfected AJ3.1 fibroblast vaccine was as potent as the
Neuro-2A tumour cell vaccine.
Leukocyte infiltration and reduced vascularisation upon
vaccination of established tumours
We then examined the histology of treated vs untreated tumours
for differences in leukocyte infiltration or vascularisation. Sections
from RPMI-treated control tumours were stained with haematox-
ylin and eosin, revealing highly vascularised regions with dense
capillary networks (Figure 5A). Larger vessels were also present
around the tumour periphery. Anti-CD45 staining showed
negligible leukocyte infiltration of control tumours (Figure 5B).
Interestingly, tumours from mice vaccinated intratumorally with
AJ-IL2/IL12 (Figure 5C) or Neuro-IL2/IL12 (Figure 5E) suggested
a decrease of capillaries within the tumour compared to
RPMI-treated controls, with most vasculature confined to the
tumour periphery. Necrotic areas could also be seen in the treated
tumours, defined by punctate nuclear staining. Anti-CD45 staining
demonstrated that tumours vaccinated intratumorally with AJ-IL2/
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Figure 2 Effect of vaccination on established tumours. A/J mice were
inoculated subcutaneously with 10
6 wild-type Neuro-2A cells, and 3, 5 and
7 days later an equal number of Neuro-IL2/IL12 or AJ-IL2/IL12 cells or
RPMI medium were injected intratumorally. Tumour growth of each animal
(n¼6 for the control group and n¼10 for the therapeutic group) is
represented by a single line.
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Figure 3 The average tumour volumes of mice bearing established
tumours after treatment with three vaccines. A/J mice were engrafted with
10
6 unmodified Neuro-2A cells and vaccinated with Neuro-IL2/IL12 or AJ-
IL2/IL12 cells or RPMI medium on days 3, 5 and 7 directly into the tumour.
By 12 days post engraftment, mice vaccinated with Neuro-IL2/IL12 or AJ-
IL2/IL12 (n¼16 per group) had significantly smaller tumours compared to
RPMI-treated controls (n¼6). Day 12 is the point when all the control
mice have to be killed due to their tumour size. Significance was
determined by t-test (***Po0.001).
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sIL12 (Figure 5D) or Neuro-IL2/IL12 (Figure 5F) had extensive
infiltration of leukocytes, particularly around the tumour
periphery. This contrasts with the absence of CD45
þ cells in
RPMI-treated control tumours (Figure 5B).
Immunological memory against tumour cells of
rechallenged mice
To establish if systemic immunological memory responses to
tumour cells had been established, tumour-free mice (n¼7 from
Neuro-IL2/IL12 and n¼9 from AJ-IL2/IL12 groups) were rechal-
lenged 3 months after the initial vaccine with 10
6 wild-type Neuro-
2A cells in the opposite flank to the original injection, with no
further vaccination. All mice in each group (100%) remained
tumour free for at least 3 months.
ELISpot and LDH assays from these rechallenged mice showed
similar results to those obtained with the vaccinated mice studied
at 12 days post engraftment (Figure 4). All the splenocytes from
these rechallenged mice released a high level of IL-2 after
incubation with Neuro-2A cells and showed a strong cytolytic
activity against Neuro-2A cells in vitro, with no significant
difference between the vaccinated mice with AJ-IL2/IL12 or
Neuro-IL2/IL12 cells (not shown). Therefore, the mice vaccinated
with cytokine-transfected fibroblasts were protected as well as
those vaccinated with Neuro-IL2/12 cells.
DISCUSSION
Neuroblastoma immunotherapy using genetically modified tumour
cells that secrete proinflammatory cytokines into the tumour
environment is a promising approach for the treatment of the
disease. However, difficulties in culturing sufficient quantities of
primary tumour cells from surgical biopsies hamper these
approaches. Autologous fibroblasts, genetically manipulated to
secrete cytokines, offer an attractive alternative approach to
cellular vaccines as they can be readily cultured and expanded
from skin biopsies. They may be transfected with genes for
proinflammatory cytokines and either injected directly into the
tumour site or mixed with tumour cells for subcutaneous injection.
In this study, we have evaluated the potential of a vaccine
consisting of syngeneic fibroblasts for immunotherapy in a murine
model of neuroblastoma and compared this vaccine with a
neuroblastoma tumour cell vaccine described previously (Siapati
et al, 2003). The A/J mouse and syngeneic Neuro-2A cells are
widely used by neuroblastoma researchers and they are considered
to represent a good model of the disease (Ziegler et al., 1997). A
metastatic model of diseases would be more clinically relevant, but
at this stage of research, subcutaneous models are convenient and
appropriate since tumours engrafted subcutaneously in the flank
are accessible for measurement and treatment. The fibroblast
vaccine consisted of an embryonic fibroblast cell line, AJ3.1,
transfected with plasmids encoding IL-2 and IL-12, while the
tumour cell vaccine comprised syngeneic Neuro-2A neuro-
blastoma cells transfected with the same plasmids. In previous
studies, the tumorigenicity in A/J mice of Neuro-2A cells
transfected with IL-2 and IL-12 (Neuro-IL2/IL12) was abolished,
and Neuro-IL2/IL12 cells injected into established tumours
generated an anti-neuroblastoma immune response, involving
both CD8
þ and CD4
þ T cells, that led to tumour eradication in
some mice (Siapati et al, 2003). The same cell-mediated mechan-
ism of immunity with the same cytokines secreted by fibroblasts as
syngeneic tumour cells is likely.
Expression of secreted IL-12 and IL-2 from transfected AJ3.1 cells
peaked at 1100ng10
6cells
 124h
 1 and 230ng10
6cells
 124h
 1,
respectively. This level of expression compared well with Neuro-
2A cells where transfected levels of IL-12 and IL-2 were 1350 and
150ng10
6cells
 124h
 1, respectively. These levels had previously
proved therapeutic for neuroblastoma in A/J mice (Siapati et al,
2003) and also compared well with levels of IL-2 and IL-12
expression reported with adenoviral vectors (Emtage et al, 1999).
In that study, PyMT and Neu murine tumour cells derived from
breast adenocarcinoma cells and transduced with Adenovirus-type
5 vectors produced 788 and 1204ng10
6cells
 124h
 1, respectively,
of IL-12, and 32 and 51ng10
6cells
 124h
 1 of IL-2 (Emtage et al,
1999). These levels of adenovirus-mediated IL-2 and IL-12
expression were effective in mediating tumour regression in a
murine model of breast cancer (Emtage et al, 1999). Therefore,
IL-2 and IL-12 secretion levels from AJ3.1 cells transfected by the
synthetic vector in this study were comparable to a viral vector
system and were sufficient to anticipate an immunological
antitumour effect. Indeed, the tumorigenicity of viable Neuro-2A
tumour cells in A/J mice was significantly reduced when
coadministered with AJ-IL2/IL12 and Neuro-IL2/IL12 vaccines,
with five of six mice in each vaccine group failing to develop
tumours.
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Figure 4 ELISpot and LDH release assays were performed using
splenocytes from mice with treated established tumours. Mice were
engrafted subcutaneously with tumour cells, then vaccinated 3, 5 and 7 days
later. On day 12, six mice from each group were culled and splenocytes
coincubated with Neuro-2A cells for 48h hours. (A) Splenocytes from
mice vaccinated with Neuro-IL2/IL12 or AJ- IL2/IL12 had significantly
greater numbers of IL-2-expressing splenocytes than RPMI-vaccinated
controls in response to Neuro-2A target cells (**Po0.01). Photographs
are of representative wells and significance was determined by t-test. (B)
LDH assay determined the cytotoxicity of splenocytes against Neuro-2A
targets using a 27:1 E:T ratio. Mice vaccinated with Neuro-IL2/IL12 or AJ-
IL2/IL12 showed significantly greater toxicity against Neuro-2A targets than
splenocytes from mice vaccinated with RPMI. Significance was determined
by t-test (*Po0.05).
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tumour growth when injected into small tumours compared with
controls. Complete tumour growth inhibition was seen in seven of
10 (70%) mice treated with the Neuro-IL2/IL12 vaccine and nine of
10 (90%) mice treated with the AJ-IL2/IL12 vaccine. The tumour-
free mice were rechallenged 3 months later by subcutaneous
injection of viable Neuro-2A cells in the opposite flank to the
original injection. All mice in each of these groups (100%) rejected
this secondary challenge, suggesting that an immune memory
response was induced by both types of vaccine.
The immune memory response in each vaccine group was
assessed by IL-2 ELISpot of splenocytes following coculture with
Neuro-2A cells, and CTL cytotoxicity against Neuro-2A target cells
in LDH-release assays. Splenocytes from Neuro-IL2/IL12 and AJ-
IL2/IL12 vaccinated groups generated similar number of spots,
while control mice produced significantly fewer levels of spots.
These findings suggested that the immune system of A/J mice
recognised the tumour, and that the antitumour immune response
in treated animals was sufficient to prevent tumour growth. After
treatment with either the fibroblast or tumour cell vaccine, the
cytotoxicity of CTLs in both vaccine groups was significantly
higher than the CTL cytotoxicity from tumour-engrafted controls.
This clearly indicated that cytokine adjuvant immunotherapy
enhances CTL cytotoxicity, preventing tumour engraftment.
Moreover, splenocyte activation and CTL cytotoxicity assays in
these experiments suggested that fibroblasts are an efficient
alternative to tumour cells for neuroblastoma vaccination.
Splenocytes from the RPMI control sample also appeared to
recognise Neuro-2A cells, producing significant numbers of spots
and were also able to lyse target cells. However, in each
experiment, these controls were significantly less active than the
vaccine groups indicating that the immune response raised was
insufficient to limit tumour growth. This observation supports the
strategy of immunotherapy for neuroblastoma, at least in this
model, since although syngeneic, the Neuro-2A cells are recognised
as foreign, perhaps by tumour-associated antigens.
Histological analysis of tumour sections showed extensive
leukocyte infiltration in tumours from animals vaccinated with
Neuro-IL2/IL12 or AJ-IL2/IL12 compared to negligible staining for
leukocytes in control tumours, suggesting that the fibroblast vaccine
recruits immune effector cells to the tumour site as effectively as the
tumour cell vaccine. As well as mediating adaptive immune
AB
CD
EF
Figure 5 Tumour histology and immunohistochemistry. Mice vaccinated with RPMI showed well vascularised tumours (black arrow) (A) and negligible
infiltration of CD45
þ leukocytes (B). Tumours showed much reduced vascularity compared to RPMI-treated controls following vaccination with AJ-IL2/IL12
(C) or Neuro-IL2/IL12 (E) with areas of necrotic tissue (*). There was also extensive infiltration of CD45
þ leukocytes (black arrow) in tumours treated with
AJ-IL2/IL12 (D) or Neuro-IL2/IL12 (F). Representative sections are shown. Magnification  40.
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histological evaluation of tumours from mice treated with Neuro-
IL2/IL12 or AJ-IL2/IL12 vaccines suggested that the vascularisation
was reduced compared to control tumours. Necrosis of tumour
tissue was another prevalent feature of tumours from vaccinated
animals, possibly due to a combination of extensive infiltration of
immune effector cells and the reduced vascular network, leading to
a limited supply of nutrients and hypoxia.
Cytokine-expressing autologous tumour cells have generally
only been used against the parental tumour, and similarly,
allogeneic tumour cells have been used only to treat tumours of
the same type. One potential major advantage of transfected
fibroblasts over transfected tumour cells is that they may be
effective against multiple tumour types. Autologous dermal
primary fibroblasts transduced with a retrovirus to express IL-2
or IL-12 have already been used in clinical trials to treat two types
of tumour (Sobol et al, 1999; Kang et al, 2001), and IL-2 engineered
syngeneic fibroblasts have also been injected intracerebrally to
treat experimental glioma (Lichtor et al, 2002).
Syngeneic fibroblasts have also shown promise as gene delivery
‘vehicles’ in a number of other experimental systems, such as
delivery of IL-4 in collagen-induced rheumatoid arthritis (Bessis
et al, 2002) and production of proteolipid protein to induce
T-cell anergy in experimental autoimmune encephalomyelitis,
the murine model of multiple sclerosis (Weiner et al, 2004).
Primary fibroblasts have also been used to deliver BDNF and
NT-3 in experimental models of spinal cord injury (Tobias et al,
2003).
In conclusion, cytokine-transfected autologous fibroblasts are a
promising alternative to tumour cells for immunotherapy of
neuroblastoma and other cancers.
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